日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

接受达雷妥尤单抗(抗CD38)或依地替尼(CSF-1R抑制剂)治疗的局限性前列腺癌患者的免疫和病理反应

Siddiqui, Bilal A; Chapin, Brian F; Jindal, Sonali; Duan, Fei; Basu, Sreyashi; Yadav, Shalini S; Gu, Ai-Di; Espejo, Alexsandra B; Kinder, Michelle; Pettaway, Curtis A; Ward, John F; Tidwell, Rebecca S S; Troncoso, Patricia; Corn, Paul G; Logothetis, Christopher J; Knoblauch, Roland; Hutnick, Natalie; Gottardis, Marco; Drake, Charles G; Sharma, Padmanee; Subudhi, Sumit K

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

JNJ-64041809(一种基于减毒活双缺失单核细胞增生李斯特菌的免疫疗法)在转移性去势抵抗性前列腺癌中的安全性和初步免疫原性

Drake, Charles G; Pachynski, Russell K; Subudhi, Sumit K; McNeel, Douglas G; Antonarakis, Emmanuel S; Bauer, Todd M; Lauer, Peter; Brockstedt, Dirk; Patricia, Daniel; Wade, Mark; Zudaire, Enrique; Bandyopadhyay, Nibedita; Parasrampuria, Dolly A; Girgis, Suzette; Mason, Gary E; Knoblauch, Roland E; Stone, Nicole; Infante, Jeffrey R; Gottardis, Marco M; Fong, Lawrence

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

发现新一代雄激素受体拮抗剂 JNJ-63576253,可对抗转移性去势抵抗性前列腺癌中的野生型和临床相关配体结合域突变

Jonathan R Branch, Tammy L Bush, Vineet Pande, Peter J Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James R Bischoff, Georges Habineza, Geert Van Hecke, Lieven Meerpoel, Kathryn Packman, Christopher J Parrett, Yolanda T Chong, Marco M Gottardis, Gilles Bignan

Stereotactic Radiofrequency Ablation of an Unresectable Intrahepatic Cholangiocarcinoma (ICC): Transforming an Aggressive Disease into a Chronic Condition

立体定向射频消融术治疗无法切除的肝内胆管癌(ICC):将侵袭性疾病转化为慢性疾病

Laimer, Gregor; Jaschke, Nikolai; Gottardis, Maximilian; Schullian, Peter; Putzer, Daniel; Sturm, Wolfgang; Bale, Reto

Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer

发现选择性CYP17A1裂解酶抑制剂BMS-351用于治疗前列腺癌

Huang, Audris; Jayaraman, Lata; Fura, Aberra; Vite, Gregory D; Trainor, George L; Gottardis, Marco M; Spires, Thomas E; Spires, Vanessa M; Rizzo, Cheryl A; Obermeier, Mary T; Elzinga, Paul A; Todderud, Gordon; Fan, Yi; Newitt, John A; Beyer, Sophie M; Zhu, Yongxin; Warrack, Bethanne M; Goodenough, Angela K; Tebben, Andrew J; Doweyko, Arthur M; Gold, David L; Balog, Aaron

Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

发现新型雄激素受体拮抗剂BMS-641988,用于治疗前列腺癌

Balog, Aaron; Rampulla, Richard; Martin, Gregory S; Krystek, Stanley R; Attar, Ricardo; Dell-John, Janet; DiMarco, John D; Fairfax, David; Gougoutas, Jack; Holst, Christian L; Nation, Andrew; Rizzo, Cheryl; Rossiter, Lana M; Schweizer, Liang; Shan, Weifang; Spergel, Steven; Spires, Thomas; Cornelius, Georgia; Gottardis, Marco; Trainor, George; Vite, Gregory D; Salvati, Mark E

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

BMS-911543(一种功能选择性 JAK2 小分子抑制剂)的表征

A V Purandare, T M McDevitt, H Wan, D You, B Penhallow, X Han, R Vuppugalla, Y Zhang, S U Ruepp, G L Trainor, L Lombardo, D Pedicord, M M Gottardis, P Ross-Macdonald, H de Silva, J Hosbach, S L Emanuel, Y Blat, E Fitzpatrick, T L Taylor, K W McIntyre, E Michaud, C Mulligan, F Y Lee, A Woolfson, T L

IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.

IGFBP 比率赋予乳腺肿瘤对 IGF 靶向治疗的抵抗力,并与乳腺肿瘤侵袭性增强和预后不良相关

Becker Marc A, Hou Xiaonan, Harrington Sean C, Weroha S John, Gonzalez Sergio E, Jacob Kristina A, Carboni Joan M, Gottardis Marco M, Haluska Paul

High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

高水平的 IGF1R 表达是 T-ALL 中白血病起始细胞活性所必需的,并由 Notch 信号支持

Hind Medyouf, Samuel Gusscott, Hongfang Wang, Jen-Chieh Tseng, Carol Wai, Oksana Nemirovsky, Andreas Trumpp, Francoise Pflumio, Joan Carboni, Marco Gottardis, Michael Pollak, Andrew L Kung, Jon C Aster, Martin Holzenberger, Andrew P Weng

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer

双重 IGF-1R/InsR 抑制剂 BMS-754807 与激素药物协同作用治疗雌激素依赖性乳腺癌

Xiaonan Hou, Fei Huang, Luciana F Macedo, Sean C Harrington, Karen A Reeves, Ann Greer, Friedrich Graf Finckenstein, Angela Brodie, Marco M Gottardis, Joan M Carboni, Paul Haluska